Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M140,592Revenue $M11,202Net Margin (%)27.5Z-Score7.6
Enterprise Value $M144,242EPS $1.8Operating Margin %40.4F-Score7
P/E(ttm))33.7Cash Flow Per Share $4.3Pre-tax Margin (%)37.6Higher ROA y-yY
Price/Book10.410-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsN
Price/Sales11.45-y EBITDA Growth Rate %0.9Current Ratio2.2Lower Leverage y-yY
Price/Cash Flow17.4y-y EBITDA Growth Rate %86.1ROA % (ttm)13.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)27.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,536ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 93.7921%Reduce -39.79%1,633,700
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 93.7920%Add 7.91%345,320
GILDRay Dalio 2014-03-31 Add0.12%$68.55 - $83.95
($78.44)
$ 93.7920%Add 541.42%247,721
GILDGeorge Soros 2014-03-31 Buy 0.04%$68.55 - $83.95
($78.44)
$ 93.7920%New holding, 50000 sh.50,000
GILDJohn Burbank 2014-03-31 Buy 0.01%$68.55 - $83.95
($78.44)
$ 93.7920%New holding, 3619 sh.3,619
GILDMario Gabelli 2014-03-31 Add$68.55 - $83.95
($78.44)
$ 93.7920%Add 31.65%44,240
GILDDaniel Loeb 2014-03-31 Sold Out -1.9%$68.55 - $83.95
($78.44)
$ 93.7920%Sold Out0
GILDJohn Griffin 2014-03-31 Sold Out -0.48%$68.55 - $83.95
($78.44)
$ 93.7920%Sold Out0
GILDVanguard Health Care Fund 2014-03-31 Reduce-0.46%$68.55 - $83.95
($78.28)
$ 93.7920%Reduce -41.41%2,713,300
GILDJulian Robertson 2013-12-31 Add1.52%$58.9 - $75.2
($69.65)
$ 93.7935%Add 25.84%320,001
GILDDaniel Loeb 2013-12-31 Add1.27%$58.9 - $75.2
($69.65)
$ 93.7935%Add 200%1,500,000
GILDRay Dalio 2013-12-31 Buy 0.02%$58.9 - $75.2
($69.65)
$ 93.7935%New holding, 38621 sh.38,621
GILDJohn Griffin 2013-12-31 Reduce-1.02%$58.9 - $75.2
($69.65)
$ 93.7935%Reduce -68.21%620,000
GILDJohn Hussman 2013-12-31 Sold Out -0.86%$58.9 - $75.2
($69.65)
$ 93.7935%Sold Out0
GILDVanguard Health Care Fund 2013-12-31 Reduce-0.4%$58.9 - $75.2
($69.65)
$ 93.7935%Reduce -28.62%4,630,700
GILDGeorge Soros 2013-12-31 Sold Out -0.02%$58.9 - $75.2
($69.65)
$ 93.7935%Sold Out0
GILDDaniel Loeb 2013-09-30 Buy 0.79%$51.98 - $64.32
($59.85)
$ 93.7957%New holding, 500000 sh.500,000
GILDMariko Gordon 2013-09-30 Add0.01%$51.98 - $64.32
($59.85)
$ 93.7957%Add 46.84%15,934
GILDMario Gabelli 2013-09-30 Add$51.98 - $64.32
($59.85)
$ 93.7957%Add 43.6%31,305
GILDJulian Robertson 2013-09-30 Reduce-0.86%$51.98 - $64.32
($59.85)
$ 93.7957%Reduce -34.29%254,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD Vanguard Health Care Fund 2014-06-301,633,7000.110.36-39.79%
GILD George Soros 2014-03-3150,00000.04New Buy
GILD John Burbank 2014-03-313,61900.01New Buy
GILD Ray Dalio 2014-03-31247,7210.020.14+541.42%
GILD Mario Gabelli 2014-03-3144,24000.02+31.65%
GILD Mariko Gordon 2014-03-3118,08900.05+17.07%
GILD Julian Robertson 2014-03-31345,3200.028+7.91%
GILD Jean-Marie Eveillard 2014-03-3140000
GILD Ronald Muhlenkamp 2014-03-31192,0150.012.4-0.4%
GILD Daniel Loeb 2014-03-31000Sold Out
GILD John Griffin 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MOORE NICHOLAS GDirector 2014-07-28Sell45,000$90.563.57view
Cogan John FrancisDirector 2014-07-21Sell5,000$89.674.59view
Carter Paul RutherfordEVP Commercial Ops 2014-07-08Sell16,728$86.458.49view
MARTIN JOHN CChairman and CEO 2014-07-01Sell140,625$84.8410.55view
Alton Gregg HEVP, Corp & Med Affairs 2014-07-01Sell33,000$84.1211.5view
Whitley Richard JamesDirector 2014-07-01Sell5,000$83.6512.12view
Washington Robin LEVP, CFO 2014-06-30Sell10,400$83.9811.68view
Cogan John FrancisDirector 2014-06-23Sell5,000$81.8214.63view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2014-06-16Sell90,000$80.915.93view
Carter Paul RutherfordEVP Commercial Ops 2014-06-09Sell16,728$79.4318.08view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Creating Cures And Dividends Where None Existed Before With Gilead Sciences Jul 26 2014 
Analyzing Why Gilead Sciences is Still a Great Buy Jul 24 2014 
Why AbbVie Looks Like a Sell Jul 18 2014 
Why Gilead Sciences Will Grow to $100 Jul 18 2014 
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 
Weekly CFO Sells Highlight: Facebook Inc, Workday Inc, Gilead Sciences Inc. Jun 23 2014 
Weekly Insider Sells Highlight: FB, NFLX, WDAY, GILD Jun 22 2014 
Julian Robertson Likes Uber, Google, Gilead, Stan Druckenmiller Jun 12 2014 
Top 5 Hedge Fund Net Buys May 21 2014 
Weekly CFO Sells Highlight: Affiliated Managers Group Inc., Gilead Sciences Inc., L-3 Communications May 19 2014 


More From Other Websites
Merck, J&J, Baxter Provide Healthy Dividend Stream Jul 30 2014
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Jul 30 2014
[video] Cramer's Mad Dash: REGN breaks through Jul 30 2014
$1,000 Sovaldi now hepatitis treatment of choice Jul 29 2014
$1,000 Sovaldi now hepatitis treatment of choice Jul 29 2014
Aetna Earnings Beat But Rising Medical Costs A Worry Jul 29 2014
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as... Jul 29 2014
Gilead's Oncology Drug Recommended for Approval in the EU Jul 28 2014
Why Gilead Sciences (GILD) Stock Is Up Today Jul 28 2014
High cost of hepatitis C treatment pills is hard to swallow Jul 27 2014
Drug cocktails point the way towards relief for all hepatitis C sufferers Jul 27 2014
Politicizing Gilead's Research And Development Costs For Sovaldi Is A Reckless And Dangerous... Jul 25 2014
[video] The push back on Sovaldi Jul 25 2014
[video] The $84,000 drug debate Jul 25 2014
[video] Drug costs hit insurers: Gilead still a buy? Jul 25 2014
Did Gilead's Sovaldi Cause WellCare's Woes? Jul 25 2014
AbbVie Beats Earnings Views, Sees Slower Humira Gain Jul 25 2014
Gilead says EU Committee to recommend approval of leukemia drug Jul 25 2014
Gilead receives positive opinion from CHMP for Zydelig Jul 25 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide